SCHEMBL1172437

SCHEMBL1172437

O=[N+]([O-])c1cc(F)cc(F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.55
TSHR P16473 2/20 0.50
ALDH1A1 P00352 5/20 0.48
HIF1A Q16665 2/20 0.46
LMNA P02545 3/20 0.46
HSPB1 P04792 1/20 0.45
MEN1 O00255 2/20 0.44
HTT P42858 2/20 0.44
KMT2A Q03164 2/20 0.44
VCAM1 P19320 1/20 0.44
TDP1 Q9NUW8 2/20 0.43
CYP3A4 P08684 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ATM Q13315 1/20 0.43
PGR P06401 1/20 0.42
POLB P06746 2/20 0.41
KDM4E B2RXH2 1/20 0.41
TTR P02766 1/20 0.41
CYP1A2 P05177 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7203812 0.94 CYP19A1 (0.62) CYP19A1TSHRALDH1A1HIF1ALMNA
Fluoride SCHEMBL27574861 0.92 CYP19A1 (0.59) CYP19A1TSHRALDH1A1HIF1ALMNA
SCHEMBL30492205 0.84 LMNA (0.47) CYP19A1TSHRALDH1A1HIF1ALMNA
SCHEMBL1171962 0.84 LMNA (0.47) CYP19A1TSHRALDH1A1HIF1ALMNA
SCHEMBL2017968 0.84 ALDH1A1 (0.50) CYP19A1TSHRALDH1A1HIF1ALMNA
SCHEMBL2649497 0.84 CYP19A1 (0.44) CYP19A1TSHRALDH1A1HIF1ALMNA
SCHEMBL16960250 0.84 CYP19A1 (0.44) CYP19A1TSHRALDH1A1HIF1ALMNA
SCHEMBL8999906 0.84 ALDH1A1 (0.50) CYP19A1TSHRALDH1A1HIF1ALMNA
SCHEMBL1944691 0.84 ALDH1A1 (0.50) CYP19A1TSHRALDH1A1MEN1HTT
SCHEMBL3844920 0.84 TSHR (0.71) CYP19A1TSHRALDH1A1HIF1ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 487 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119504636-A Preparation method of 2- (4-fluorophenyl) -6-nitro-4- (2, 2-trifluoroethoxy) -1, 2-benzothiazole-3-ketone and intermediate and application thereof 上海筛杰生物医药有限公司 2025-02-25 CN claimed
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 US claimed
JP-7017923-A None JP disclosed
WO-2026090477-A1 HELICASE INHIBITORS AND USES THEREOF KIMIA THERAPEUTICS, INC. (US) 2026-04-30 WO disclosed
EP-3985001-B1 PHARMACEUTICAL COMPOSITION FOR USE IN TREATING A CANCER SERVIER LAB (FR) 2026-04-29 EP disclosed
US-12583815-B2 Inhibitors of YAP/TAZ-TEAD oncoproteins, synthesis and use thereof BRIDGENE BIOSCIENCES, INC. (US) 2026-03-24 US disclosed
CN-119504636-B Preparation method of 2- (4-fluorophenyl) -6-nitro-4- (2, 2-trifluoroethoxy) -1, 2-benzothiazole-3-ketone and intermediate and application thereof 上海筛杰生物医药有限公司 2026-03-13 CN disclosed
EP-4334298-B1 UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER SCORPION THERAPEUTICS INC (US) 2026-02-18 EP disclosed
US-12540129-B2 KIF18A inhibitors AMGEN INC. (US) 2026-02-03 US disclosed
EP-4673137-A1 NBD1 MODULATORS AND METHODS OF USING THE SAME Sionna Therapeutics Inc. (US) 2026-01-07 EP disclosed
US-20250382283-A1 COMPOUNDS AND THEIR USES AS CD38 INHIBITORS NANJING IMMUNOPHAGE BIOTECH CO LTD (CN) 2025-12-18 US disclosed
EP-0491968-A1 Process for the preparation of N-alkyl-fluoroanilines BAYER AG (DE) 1992-07-01 EP disclosed
US-4721790-A Nucleophilic substitution process for fluoronitroaralkyloxazoline ETHYL CORPORATION (US) 1988-01-26 US disclosed
EP-0150418-B1 PROCESS FOR PREPARING FLUORINATED AROMATIC COMPOUNDS BASF Aktiengesellschaft (DE) 1987-03-04 EP disclosed
US-4568781-A Preparation of fluorine-substituted aromatic compounds BASF AKTIENGESELLSCHAFT (DE) 1986-02-04 US disclosed
US-4540795-A Fluoronitroaralkyloxazolines, derivatives thereof, and nucleophilic substitution processes for preparing them ETHYL CORPORATION (US) 1985-09-10 US disclosed
EP-0150418-A1 Process for preparing fluorinated aromatic compounds BASF Aktiengesellschaft (DE) 1985-08-07 EP disclosed
US-4476337-A Method for introducing fluorine into an aromatic ring THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) 1984-10-09 US disclosed
US-4423260-A Method for introducing fluorine into an aromatic ring THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) 1983-12-27 US disclosed
US-4370278-A Nucleophilic substitution process ETHYL CORPORATION (US) 1983-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583815-B2 Inhibitors of YAP/TAZ-TEAD oncoproteins, synthesis and use thereof YAP1, TEAD1, TEAD2 CYP19A1 4474/4885TSHR 1551/4885ALDH1A1 3155/4885
US-12540129-B2 KIF18A inhibitors KIF18A, KIFC1, KIF2C CYP19A1 1310/4885TSHR 2351/4885ALDH1A1 802/4885
US-20250382283-A1 COMPOUNDS AND THEIR USES AS CD38 INHIBITORS CD38, FCGRT, CD22 CYP19A1 2163/4885TSHR 3533/4885ALDH1A1 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.